Summary: 1. How functional imaging is different from anatomic imaging2. Different tracers - FDG, NAF, DOTATATE, AXUMIN, PSMA3. Limitations (size, lack of contrast in some places)4. Pitfalls - know expected physiologic uptake and other processes that cause uptake5. Future of PET - exciting implications for therapies Host: Christopher Cerniglia, DO, ME, FAOCR. Associate Professor of Radiology, Division of Musculoskeletal Imaging & Intervention, UMMS Dept of Radiology.Guest: Lacey J McIntosh DO, MPH. Assistant Professor of Radiology, Divisions of Abdominal Imaging and Nuclear Medicine, UMMS Dept of Radiology.

Resources:1. Kapoor, V., McCook, B. M., & Torok, F. S. (2004). An introduction to PET-CT imaging. Radiographics, 24(2), 523-543..2. Bar-Shalom, R., Valdivia, A. Y., & Blaufox, M. D. (2000, July). PET imaging in oncology. In Seminars in nuclear medicine (Vol. 30, No. 3, pp. 150-185). WB Saunders.3. Wallitt, K., Yusuf, S., Soneji, N., Khan, S. R., Win, Z., & Barwick, T. D. (2018). PET/CT in Oncologic Imaging of Nodal Disease: Pearls and Pitfalls: RadioGraphics Fundamentals| Online Presentation. RadioGraphics, 38(2), 564-565.4. Wang, G. X., Kurra, V., Gainor, J. F., Sullivan, R. J., Flaherty, K. T., Lee, S. I., & Fintelmann, F. J. (2017). Immune checkpoint inhibitor cancer therapy: spectrum of imaging findings. Radiographics, 37(7), 2132-2144.